Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced updated results from ELPIS II
Longeveron's medicine for sick babies did not work as hoped. When a company's test fails, watch if they have other ideas or run out of money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.